The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Y 20811     sodium4-[hydroxy-(5-imidazol- 1-yl-2...

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of 4-[hydroxy-(5-imidazol-1-yl-2-methyl-phenyl)methyl]-3,5-dimethyl-benzoic acid


High impact information on 4-[hydroxy-(5-imidazol-1-yl-2-methyl-phenyl)methyl]-3,5-dimethyl-benzoic acid


Chemical compound and disease context of 4-[hydroxy-(5-imidazol-1-yl-2-methyl-phenyl)methyl]-3,5-dimethyl-benzoic acid


Biological context of 4-[hydroxy-(5-imidazol-1-yl-2-methyl-phenyl)methyl]-3,5-dimethyl-benzoic acid

  • Administered orally to rabbits, Y-20811 at a dose of 1 mg/kg decreased serum TXB2 concomitant with increasing 6-keto PGF1 alpha and at a dose of 3 mg/kg inhibited AA-induced platelet aggregation, in both cases for at least 48 hours [6].
  • The drugs were orally administered to rabbits at 24 and 1 hour before injection of endotoxin (5 mg/kg, i.v.). Y-20811 (1 mg/kg) promoted the recovery of decreased platelet counts, and inhibited hypotension induced by endotoxin [7].

Anatomical context of 4-[hydroxy-(5-imidazol-1-yl-2-methyl-phenyl)methyl]-3,5-dimethyl-benzoic acid


Associations of 4-[hydroxy-(5-imidazol-1-yl-2-methyl-phenyl)methyl]-3,5-dimethyl-benzoic acid with other chemical compounds


Analytical, diagnostic and therapeutic context of 4-[hydroxy-(5-imidazol-1-yl-2-methyl-phenyl)methyl]-3,5-dimethyl-benzoic acid

  • Serum TXA2 (estimated as TXB2) production was inhibited significantly from 1 to 72 hr after the oral administration of unlabeled Y-20811 (3 mg/kg), which temporally resembled the change of the platelet Y-20811 concentration [5].
  • The level of i-6-keto PGF1 alpha tended to increase slightly in the Y-20811-treated, but not in the control group [1].


  1. Effects of Y-20811, a thromboxane A2 synthetase inhibitor, on experimentally induced coronary thrombosis in anesthetized dogs. Matsumoto, Y., Ochi, H., Aihara, K., Inui, J., Ikegami, K. Eur. J. Pharmacol. (1992) [Pubmed]
  2. Effects of a thromboxane synthetase inhibitor, Y-20811, on infarct size, neutrophil accumulation, and arrhythmias after coronary artery occlusion and reperfusion in dogs. Sato, N., Endo, T., Kiuchi, K., Hayakawa, H. J. Cardiovasc. Pharmacol. (1993) [Pubmed]
  3. Effect of Y-20811, a thromboxane synthetase inhibitor, on photochemically induced cerebral embolism in rabbits. Fujimura, M., Mikashima, H. Thromb. Res. (1993) [Pubmed]
  4. Nitric oxide-induced Cl- secretion in isolated rat colon is mediated by the release of thromboxane A2. Sakai, H., Suzuki, T., Murota, M., Takahashi, Y., Takeguchi, N. J. Physiol. (Lond.) (2002) [Pubmed]
  5. Irreversible inhibition of thromboxane (TX) A2 synthesis by Y-20811, a selective TX synthetase inhibitor. Mikashima, H., Ochi, H., Muramoto, Y., Hirotsu, K., Arima, N. Biochem. Pharmacol. (1992) [Pubmed]
  6. Effects of Y-20811, a long-lasting thromboxane synthetase inhibitor, on thromboxane production and platelet function. Mikashima, H., Ochi, H., Muramoto, Y., Yasuda, H., Tsuruta, M., Maruyama, Y. Thromb. Res. (1986) [Pubmed]
  7. Protective effect of Y-20811, a long-lasting thromboxane synthetase inhibitor, on endotoxin shock in rabbits. Mikashima, H., Muramoto, Y. Thromb. Res. (1990) [Pubmed]
  8. Effect of Y-20811, a long-lasting thromboxane A2 synthetase inhibitor, on antigen-induced airway hyperresponsiveness in guinea pigs. Kagoshima, M., Tomomatsu, N., Aratani, H., Terasawa, M. Int. Arch. Allergy Appl. Immunol. (1991) [Pubmed]
  9. Phase I study of Y-20811, a new long-acting thromboxane synthetase inhibitor by oral administration. Nakashima, M., Uematsu, T., Takiguchi, Y., Mizuno, A., Kanamaru, M. Journal of clinical pharmacology. (1989) [Pubmed]
WikiGenes - Universities